These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 22889816)

  • 1. Futility of testing for factor V Leiden.
    Favaloro EJ; McDonald D
    Blood Transfus; 2012 Jul; 10(3):260-3. PubMed ID: 22889816
    [No Abstract]   [Full Text] [Related]  

  • 2. Utility of testing for factor V Leiden.
    Franchini M
    Blood Transfus; 2012 Jul; 10(3):257-9. PubMed ID: 22889815
    [No Abstract]   [Full Text] [Related]  

  • 3. Factor V Leiden: to test or not to test, that is the debate.
    Makris M
    Blood Transfus; 2012 Jul; 10(3):255-6. PubMed ID: 22889814
    [No Abstract]   [Full Text] [Related]  

  • 4. Effect of exogenous estrogen on atherothrombotic vascular disease risk related to the presence or absence of the factor V Leiden mutation (resistance to activated protein C).
    Glueck CJ; Wang P; Fontaine RN; Tracy T; Sieve-Smith L; Lang JE
    Am J Cardiol; 1999 Sep; 84(5):549-54. PubMed ID: 10482153
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Factor V mutations in Iranian patients with activated protein C resistance and venous thrombosis.
    Chegeni R; Kazemi B; Hajifathali A; Pourfathollah A; Lari GR
    Thromb Res; 2007; 119(2):189-93. PubMed ID: 16542711
    [No Abstract]   [Full Text] [Related]  

  • 6. Factor V Leiden gene mutation in three South African families.
    Rubinstein R; Bowers D; Novitzky N; Louw I; Jacobs P
    S Afr Med J; 1999 Feb; 89(2):176. PubMed ID: 10191872
    [No Abstract]   [Full Text] [Related]  

  • 7. The predictability of factor V Leiden (FV:Q(506)) gene mutation via clotting-based diagnosis of activated protein C resistance.
    Sayinalp N; Haznedaroğlu IC; Aksu S; Büyükaşik Y; Göker H; Parlak H; Ozcebe OI; Kirazli S; Dündar SV; Gürgey A
    Clin Appl Thromb Hemost; 2004 Jul; 10(3):265-70. PubMed ID: 15247984
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Thrombo-embolic disease--prevalence of factor V Leiden in the Western Cape.
    Rubinstein R; Novitzky N
    S Afr Med J; 2001 May; 91(5):406. PubMed ID: 11455804
    [No Abstract]   [Full Text] [Related]  

  • 9. Activated protein C resistance, the factor V Leiden mutation, and a laboratory testing algorithm.
    Van Cott EM; Soderberg BL; Laposata M
    Arch Pathol Lab Med; 2002 May; 126(5):577-82. PubMed ID: 11958664
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Coagulation factor V Leiden mutation was detected in the patients with activated protein C resistance in Thailand.
    Arnutti P; Hiyoshi M; Prayoonwiwat W; Nathalang O; Suwanasophon C; Kokaseam R; Tatsumi N
    Thromb Haemost; 1998 Aug; 80(2):344-5. PubMed ID: 9716166
    [No Abstract]   [Full Text] [Related]  

  • 11. Activated protein C resistance assay and factor V Leiden.
    Prüller F; Weiss EC; Raggam RB; Cervar-Zivkovic M; Renner W; Wagner J; Michaelis S; März W; Mangge H
    N Engl J Med; 2014 Aug; 371(7):685-6. PubMed ID: 25119624
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Identification and functional characterization of a novel F5 mutation (Ala512Val, FVB onn ) associated with activated protein C resistance.
    Pezeshkpoor B; Castoldi E; Mahler A; Hanel D; Müller J; Hamedani NS; Biswas A; Oldenburg J; Pavlova A
    J Thromb Haemost; 2016 Jul; 14(7):1353-63. PubMed ID: 27090446
    [TBL] [Abstract][Full Text] [Related]  

  • 13. High frequency of factor V Leiden mutation and prothrombin 20210A variant in Romanies of Eastern Hungary.
    Balogh I; Póka R; Losonczy G; Muszbek L
    Thromb Haemost; 1999 Nov; 82(5):1555-6. PubMed ID: 10595655
    [No Abstract]   [Full Text] [Related]  

  • 14. Cardiovascular implications of the factor V Leiden mutation.
    Major DA; Sane DC; Herrington DM
    Am Heart J; 2000 Aug; 140(2):189-95. PubMed ID: 10925328
    [No Abstract]   [Full Text] [Related]  

  • 15. Factor V Leiden haplotypes in two homozygotes of Asian origin.
    Rees DC; Clarke K; Martin PG; Keeling DM
    Br J Haematol; 1998 Sep; 102(5):1381-2. PubMed ID: 9753076
    [No Abstract]   [Full Text] [Related]  

  • 16. The frequency of factor V Leiden and prothrombin G20210A mutations in Slovak and Roma (Gypsy) ethnic group of Eastern Slovakia.
    Bôžiková A; Gabriková D; Sovičová A; Behulová R; Mačeková S; Boroňová I; Petrejčíková E; Soták M; Bernasovská J; Bernasovský I
    J Thromb Thrombolysis; 2012 Oct; 34(3):406-9. PubMed ID: 22562116
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Basilar artery thrombosis in a child heterozygous for factor V Leiden mutation.
    Verdú A; Cazorla MR; Granados MA; Alonso JA; Casado LF
    Pediatr Neurol; 2001 Jan; 24(1):69-71. PubMed ID: 11182285
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Interpreting results from Factor V Leiden mutation analysis: a cautionary note.
    Sinclair GD; Poon MC
    Clin Appl Thromb Hemost; 2013; 19(1):106-7. PubMed ID: 23034579
    [No Abstract]   [Full Text] [Related]  

  • 19. [Idiopathic intracranial hypertension and factor V Leiden mutation].
    Younes S; Aissi M; Chérif Y; Daoussi N; Boughammoura A; Frih Ayed M; Sfar MH; Jerbi S
    J Mal Vasc; 2014 Jul; 39(4):270-3. PubMed ID: 24908418
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Activated protein C resistance and factor V Leiden mutation can be associated with first-as well as second-trimester recurrent pregnancy loss.
    Younis JS; Brenner B; Ohel G; Tal J; Lanir N; Ben-Ami M
    Am J Reprod Immunol; 2000 Jan; 43(1):31-5. PubMed ID: 10698038
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.